Advancements in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy

S.R.M. Bus

Advancements in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy

S.R.M. Bus

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare heterogeneous autoimmune neuropathy that generally responds well to treatment. The treatment of CIDP can be divided into two distinct phases, each with its own treatment objectives. The first phase is induction therapy, which aims to achieve improvement in disability, remission as well as limit residual

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	Universiteit van Amsterdam
Supervisors/Advisors	van Schaik, Ivo, Supervisor Eftimov, Filip, Co-supervisor Wieske, Luuk, Co-supervisor
Award date	21 Jan 2026
Print ISBNs	9789465229744
Publication status	Published - 2026

Access to Document

https://hdl.handle.net/11245.1/32818a92-1037-43c0-ba2e-83ec7ccce14e

Cite this

@phdthesis{d1a7c2507ddd431f89fb5adbe27c6392,

title = "Advancements in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy",

abstract = "Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare heterogeneous autoimmune neuropathy that generally responds well to treatment. The treatment of CIDP can be divided into two distinct phases, each with its own treatment objectives. The first phase is induction therapy, which aims to achieve improvement in disability, remission as well as limit residual",

author = "S.R.M. Bus",

year = "2026",

language = "English",

isbn = "9789465229744",

type = "Phd-Thesis - Research and graduation internal",

school = "Universiteit van Amsterdam",

}

TY - THES

T1 - Advancements in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy

AU - Bus, S.R.M.

PY - 2026

Y1 - 2026

N2 - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare heterogeneous autoimmune neuropathy that generally responds well to treatment. The treatment of CIDP can be divided into two distinct phases, each with its own treatment objectives. The first phase is induction therapy, which aims to achieve improvement in disability, remission as well as limit residual

AB - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare heterogeneous autoimmune neuropathy that generally responds well to treatment. The treatment of CIDP can be divided into two distinct phases, each with its own treatment objectives. The first phase is induction therapy, which aims to achieve improvement in disability, remission as well as limit residual

M3 - Phd-Thesis - Research and graduation internal

SN - 9789465229744

ER -

Advancements in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Abstract

Access to Document

Fingerprint

Cite this